Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Fatal Fungal Disease
4.2.2 Favourable Reimbursement Policies
4.2.3 New and Advanced Treatment Opportunities
4.3 Market Restraints
4.3.1 Adverse Effects of the Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Amphotericin B
5.1.2 Flucytosine
5.1.3 Fluconazole
5.1.4 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astellas Pharma Inc
6.1.2 Bristol-Myers Squibb Company
6.1.3 Glenmark Pharmaceuticals
6.1.4 Janssen Biotech Inc. (Johnson & Johnson)
6.1.5 Novartis AG
6.1.6 Pfizer Inc.
6.1.7 Sigmapharm Laboratories LLC
6.1.8 Valeant Pharmaceuticals Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS